Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
BUSINESS
Chugai Closes Book with Double-Digit Earnings Growth on Overseas Sales, Royalties
Chugai Pharmaceutical ended its fiscal year 2020 with double digit growth on revenue and profits as overseas sales of Actemra (tocilizumab) and Hemlibra (emicizumab) as well as royalties rose sharply to more than offset its downbeat performance at home. In…
To read the full story
Related Article
- Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
April 26, 2022
- Chugai’s Sales and Profit Rose for 5 Years Running, 1 Trillion Yen-Plus Expected in 2022
February 4, 2022
- Chugai’s 9-Month Sales Up 17.5% on Ronapreve, 42.8 Billion Yen Booked in Govt Purchase
October 25, 2021
- Chugai’s H1 Sales Rise on Growth of Tecentriq, Kadcyla
July 27, 2021
- Chugai’s Q1 Sales Slide 5.9% on Drug Price Cuts, Gx, Frontloaded Actemra Exports
April 23, 2021
- Chugai Targets 1 Global Product Launch Each Year: New Growth Strategy
February 8, 2021
- Chugai Enjoys Higher Earnings in January-September on Hemlibra
October 23, 2020
- Chugai’s Half-Year Earnings Surge on Actemra/Hemlibra Exports
July 28, 2020
- Chugai’s Q1 Earnings Brisk on Hemlibra, Oncology Franchise
April 24, 2020
- Chugai’s 2019 Earnings Renews Record for Third Year on Hemlibra, Tecentriq
January 31, 2020
- Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
BUSINESS
- Espha Taps Korean Eylea Follow-On for First Biosimilar Foray
November 4, 2026
- Takara Bio, S-RACMO Finalize Cell Processing CDMO Transfer for January
November 4, 2026
- Roche Launches CDx for Takeda’s Elahere in Japan
November 4, 2026
- Santen’s Myopia Drug Bags Approval in South Korea
November 4, 2026
- Daiichi Sankyo H1 Revenue Zooms 20% as ADCs Drive Growth
November 2, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…